Form 8-K - Current report:
SEC Accession No. 0000950103-25-007282
Filing Date
2025-06-12
Accepted
2025-06-12 09:01:23
Documents
14
Period of Report
2025-06-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dp230070_8k.htm   iXBRL 8-K 30417
2 EXHIBIT 10.1 dp230070_ex1001.htm EX-10.1 150459
3 EXHIBIT 10.2 dp230070_ex1002.htm EX-10.2 63624
  Complete submission text file 0000950103-25-007282.txt   473453

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adct-20250611.xsd EX-101.SCH 3035
5 XBRL LABEL FILE adct-20250611_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE adct-20250611_pre.xml EX-101.PRE 22372
17 EXTRACTED XBRL INSTANCE DOCUMENT dp230070_8k_htm.xml XML 3652
Mailing Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066
Business Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066 41 21 653 02 00
ADC Therapeutics SA (Filer) CIK: 0001771910 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39071 | Film No.: 251041778
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)